A meta-analysis of the effects of insulin sensitizers in PCOS patients showed that GLP-1 receptor agonists are superior to metformin in improving insulin sensitivity, and metformin is superior to thiazolidinediones in decreasing BMI. The gene discussed is INS; the disease is polycystic ovary syndrome.